Small cell lung cancer treatment receives orphan drug designation

April 2008
Hem/Onc Today;4/25/2008, Vol. 9 Issue 7, p22
The article reports on the U.S. Food and Drug Administration's designation of orphan drug to Amrubicin. The drug is considered a third-generation anthracycline analogue used for the treatment of small cell lung cancer. Being an orphan drug gives it seven years of reduction in regulatory fee, market exclusivity and support for research and development.


Related Articles

  • PERSONALIZED MEDICINE: Keeping Up with Change. Tufel, Gary // Clinical Lab Products;Jun2013, Vol. 43 Issue 6, p8 

    The article discusses developments in personalized medicine diagnostics as of June 2013. The U.S. Food and Drug Administration (FDA) has announced its approval of Tarceva for its use in first-line treatment of non-small cell lung cancer. It observes that personalized medicine continue to present...

  • Discovering the Signs for Iressa Failure.  // Drug Discovery & Development;Sep2005, Vol. 8 Issue 9, p16 

    Reports that researchers at the Cedars-Sinai Medical Center, Los Angeles have identified a protein called EMP-1 that is present in the tumors of patients with non small-cell lung cancer who fail to response to treatment with gefitinib. Potential of the EMP-1 protein to identify patients who will...

  • Eli Lilly: Alimta receives US green light for lung cancer.  // PharmaWatch: Monthly Review;Nov2008, Vol. 7 Issue 11, p9 

    The authors reflect on the approval of FDA for Eli Lilly & Co.'s Alimta for use as a first line therapy in locally advanced and metastatic non-small cell lung cancer (NSCLC) in combination with cisplatin. They refer to NSCLC as a group of histologies where tumor types can be differentiated by...

  • Gilotrif approved for late-stage NSCLC.  // Hem/Onc Today;8/10/2013, Vol. 14 Issue 15, p26 

    The article reports on the move by the U.S. Food and Drug Administration (FDA) as of August 2013 to authorize afatinib or Gilotrif from Boehringer Ingelheim as a treatment for patients with late-stage metastatic non-small cell lung cancer (NSCLC).

  • Cell Therapeutics: hoping for a rich performance.  // PharmaWatch: Monthly Review;Mar2006, Vol. 5 Issue 3, p6 

    The article discusses the future of Cell Therapeutics Inc.' Xyotax, a biologically-enhanced version of Bristol-Myers Squibb's Taxol. It consists of paclitaxel linked to a novel polymer, which reduces the toxicity and administration issues associated with paclitaxel. The United States Food and...

  • Clinical Trial of Iressa.  // FDA Consumer;Mar/Apr2005, Vol. 39 Issue 2, p4 

    Focuses on the findings of a clinical trial conducted by AstraZeneca Pharmaceuticals comparing the drug Iressa with a placebo. Involvement of people with non-small cell lung cancer in the study; Therapeutic applications of Iressa; Requirements of the U.S. Food and Drug Administration to approve...

  • FDA Approves A New Chemo Combination For Lung CA. Bauer, Jeff; Hurley, Mary Lou // RN;Nov2006, Vol. 69 Issue 11, p51 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of the use of a drug combination for treating non-small cell lung cancer (NSCLC). Bevacizumab has received FDA approval in 2006 to be used in combination with carboplatin and paclitaxel. The combination is an...

  • Eli Lilly lung cancer drug gains FDA approval.  // PharmaWatch: Cancer;October 2004, Vol. 3 Issue 10, p10 

    This article reports that Eli Lilly & Co. lung cancer drug gains FDA approval. Indianapolis-based Eli Lilly has revealed the FDA approval of Alimta to treat the most common form of lung cancer. Alimta secured accelerated approval for the treatment of non-small cell lung cancer after data...

  • Regulatory Update.  // PharmaWatch: Cancer;Jan2006, Vol. 5 Issue 1, p9 

    The article offers news briefs related to cancer research. GlaxoSmithKline PLC's anticancer drug Hycamtin has got a positive opinion from the European Committee for Human Medicinal Products for the treatment of patients with relapsed small cell lung cancer. The U.S. Food and Drug Administration...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics